Developments and controversies in the management of oesophageal and gastric varices

Gut

Volumn 59, Issue 6, 2010, Pages 701-705

  Mehta, Gautam ^a   Abraldes, Juan G ^b   Bosch, Jaime ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CYANOACRYLATE; ISOSORBIDE; NADOLOL; PLACEBO; PROPRANOLOL; TIMOLOL;

CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG INHIBITION; ELASTOGRAPHY; ENDOSCOPY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS VARICES; HUMAN; LIGATION; MORTALITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCREENING TEST; STOMACH ULCER; STOMACH VARICES; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT RESPONSE; VENOUS PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; ESOPHAGEAL AND GASTRIC VARICES; ESOPHAGOSCOPY; GASTROINTESTINAL HEMORRHAGE; HUMANS; MASS SCREENING; PORTAL PRESSURE;

EID: 77953717663     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.201434     Document Type: Review

References (56)

1. Stokkeland K, Brandt L, Ekbom A, et al. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002. Hepatology 2006;43:500-5.
2. El-Serag HB, Everhart JE. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol 2000;95:3566-73.
3. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-76.
4. Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922-38.
5. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-61.
6. North Italian Endscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988;319:983-9.
7. Zoli M, Merkel C, Magalotti D, et al. Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. Hepatology 1996;24:1047-52.
8. Giannini E, Botta F, Borro P, et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 2003;52:1200-5.
9. Agha A, Anwar E, Bashir K, et al. External validation of the platelet count/spleen diameter ratio for the diagnosis of esophageal varices in hepatitis C virus-related cirrhosis. Dig Dis Sci 2009;54:654-60.
10. Giannini EG, Zaman A, Kreil A, et al. Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study. Am J Gastroenterol 2006;101:2511-19.
11. Qamar AA, Grace ND, Groszmann RJ, et al. Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology 2008;47:153-9.
12. Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007;45:1290-7.
13. Castera L, Le Bail B, Roudot-Thoraval F, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol 2009;50:59-68.
14. Eisen GM, Eliakim R, Zaman A, et al. The accuracy of PillCam ESO capsule endoscopy versus conventional upper endoscopy for the diagnosis of esophageal varices: a prospective three-center pilot study. Endoscopy 2006;38:31-5.
15. Groce JR, Raju GS, Sood GK, et al. A prospective single blinded comparative trial of capsule esophagoscopy vs. traditional EGD for variceal screening. Gastroenterology 2007;132:A802.
16. Pena LR, Cox T, Koch AG, et al. Study comparing oesophageal capsule endoscopy versus EGD in the detection of varices. Dig Liver Dis 2008;40:216-23.
17. de Franchis R, Eisen GM, Laine L, et al. Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension. Hepatology 2008;47:1595-603.
18. Lapalus MG, Ben Soussan E, Gaudric M, et al. Esophageal capsule endoscopy vs. EGD for the evaluation of portal hypertension: a French prospective multicenter comparative study. Am J Gastroenterol 2009;104:1112-18.
19. Perri RE, Chiorean MV, Fidler JL, et al. A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. Hepatology 2008;47:1587-94.
20. Kim SH, Kim YJ, Lee JM, et al. Esophageal varices in patients with cirrhosis: multidetector CT esophagography comparison with endoscopy. Radiology 2007;242:759-68.
21. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481-8.
22. D'Amico G, Garcia-Pagan JC, Luca A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006;131:1611-24.
23. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401-7. (Pubitemid 20381877)
24. Bureau C, Peron JM, Alric L, et al. "A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002;36:1361-6.
25. Garcia-Tsao G, Bosch J. Management of varices and variceal haemorrhage in cirrhosis. N Engl J Med 2010;362:823-32.
26. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475-505. (Pubitemid 30032646)
27. Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet 2003;361:952-4
28. Chen W, Nikolova D, Frederiksen SL, et al. Betablockers reduce mortality in cirrhotic patients with oesophageal varices who have never bled (Cochrane review). J Hepatol 2004;40(Suppl 1):A67.
29. Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004;127:476-84.
30. Turnes J, Garcia-Pagan JC, Abraldes JG, et al. Pharmacological reduction of portal pressure and longterm risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol 2006;101:506-12.
31. Sharma P, Kumar A, Sharma BC, et al. Early identification of haemodynamic response to pharmacotherapy is essential for primary prophylaxis of variceal bleeding in patients with 'high-risk' varices. Aliment Pharmacol Ther 2009;30:48-60.
32. Garcia-Pagan JC, Morillas R, Banares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology 2003;37:1260-6.
33. Gournay J, Masliah C, Martin T, et al. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000;31:1239-45. (Pubitemid 30351284)
34. Feu F, Bordas JM, Luca A, et al. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology 1993;18:1082-9.
35. Thalheimer U, Triantos CK, Samonakis DN, et al. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005;54:556-63.
36. Perez-Paramo M, Munoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000;31:43-8. (Pubitemid 30033687)
37. Senzolo M, Cholongitas E, Burra P, et al. Beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009;29:1189-93.
38. Khuroo MS, Khuroo NS, Farahat KL, et al. Metaanalysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther 2005;21:347-61.
39. Garcia-Pagan JC, Bosch J. Endoscopic band ligation in the treatment of portal hypertension. Nat Clin Pract Gastroenterol Hepatol 2005;2:526-35.
40. Gluud LL, Klingenberg S, Nikolova D, et al. Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol 2007;102:2842-8.
41. Bosch J, Berzigotti A, Garcia-Pagan JC, et al. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008;48(Suppl 1):S68-92.
42. Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed: a multicenter trial. Hepatology 2005;41:572-8.
43. Lo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 2009;50:825-33.
44. Schepke M, Kleber G, Nurnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004;40:65-72.
45. Norberto L, Polese L, Cillo U, et al. A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl 2007;13:1272-8.
46. de la Pena J, Brullet E, Sanchez-Hernandez E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2000;32:461-5.
47. Kumar A, Jha SK, Sharma P, et al. Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology 2009;137:892-901.
48. Garcia-Pagan JC, Villanueva C, Albillos A, et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut 2009;58:1144-50.
49. Lo GH, Chen WC, Chan HH, et al. A randomized controlled trial of banding ligation plus drug therapy versus drug therapy alone in the prevention of esophageal variceal rebleeding. J Gastroenterol Hepatol 2009;24:982-7.
50. Sarin SK, Lahoti D, Saxena SP, et al. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 1992;16:1343-9.
51. Triantos C, Vlachogiannakos J, Armonis A, et al. Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta-blockers: a randomized trial of ligation. Aliment Pharmacol Ther 2005;21:1435-43.
52. Mishra SR, Sharma B, Kumar A, et al. Primary prophylaxis of gastric variceal bleed comparing cyanoacrylate injection and beta-blockers. Hepatology 2009;50(Suppl 4):403A.
53. Evrard S, Dumonceau JM, Delhaye M, et al. Endoscopic histoacryl obliteration vs. propranolol in the prevention of esophagogastric variceal rebleeding: a randomized trial. Endoscopy 2003;35:729-35.
54. Lo GH, Liang HL, Chen WC, et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy 2007;39:679-85.
55. Matsumoto A, Hamamoto N, Nomura T, et al. Balloon-occluded retrograde transvenous obliteration of high risk gastric fundal varices. Am J Gastroenterol 1999;94:643-9.
56. Cho SK, Shin SW, Lee IH, et al. Balloon-occluded retrograde transvenous obliteration of gastric varices: outcomes and complications in 49 patients. AJR Am J Roentgenol 2007;189:W365-72.